Common corruption of the mTOR signaling network in human tumors

被引:268
作者
Menon S. [1 ]
Manning B.D. [1 ]
机构
[1] Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, MA
关键词
Akt; Cancer therapy; MTOR; Rapamycin; TSC1/TSC2; Tumor syndromes;
D O I
10.1038/onc.2009.352
中图分类号
学科分类号
摘要
The mammalian target of rapamycin (mTOR) is responsive to numerous extracellular and intracellular cues and, through the formation of two physically and functionally distinct complexes, has a central role in the homeostatic control of cell growth, proliferation and survival. Through the aberrant activation of mTOR signaling, the perception of cellular growth signals becomes disconnected from the processes promoting cell growth, and this underlies the pathophysiology of a number of genetic tumor syndromes and cancers. Here, we review the oncogenes and tumor suppressors comprising the regulatory network upstream of mTOR, highlight the human cancers in which mTOR is activated and discuss how dysregulated mTOR signaling provides tumors a selective growth advantage. In addition, we discuss why activation of mTOR, as a consequence of distinct oncogenic events, results in diverse clinical outcomes, and how the complexity of the mTOR signaling network might dictate therapeutic approaches. © 2009 Macmillan Publishers Limited. All rights reserved.
引用
收藏
页码:S43 / S51
页数:8
相关论文
共 113 条
[1]  
Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., Et al., EMBO J, 15, pp. 6541-6551, (1996)
[2]  
Bissler J.J., McCormack F.X., Young L.R., Elwing J.M., Chuck G., Leonard J.M., Et al., Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis, N Engl J Med, 358, pp. 140-151, (2008)
[3]  
Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., Et al., A mammalian protein targeted by G1-arresting rapamycin-receptor complex, Nature, 369, pp. 756-758, (1994)
[4]  
Cancer Genome Atlas Research Network, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 455, pp. 1061-1068, (2008)
[5]  
Carriere A., Cargnello M., Julien L.A., Gao H., Bonneil E., Thibault P., Et al., Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation, Curr Biol, 18, pp. 1269-1277, (2008)
[6]  
Castellvi J., Garcia A., Rojo F., Ruiz-Marcellan C., Gil A., Baselga J., Et al., Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer, Cancer, 107, pp. 1801-1811, (2006)
[7]  
Chakravarti A., Zhai G., Suzuki Y., Sarkesh S., Black P.M., Muzikansky A., Et al., The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas, J Clin Oncol, 22, pp. 1926-1933, (2004)
[8]  
Chiang G.G., Abraham R.T., Targeting the mTOR signaling network in cancer, Trends Mol Med, 13, pp. 433-442, (2007)
[9]  
Chiu M.I., Katz H., Berlin V., RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex, Proc Natl Acad Sci USA, 91, pp. 12574-12578, (1994)
[10]  
Choi K.M., McMahon L.P., Lawrence J.C., Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor, J Biol Chem, 278, pp. 19667-19673, (2003)